|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC01285 |
Gene summary for LINC01285 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC01285 | Gene ID | 101928287 |
| Gene name | long intergenic non-protein coding RNA 1285 | |
| Gene Alias | LINC01285 | |
| Cytomap | Xq24 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 101928287 | LINC01285 | LZE8T | Human | Esophagus | ESCC | 3.19e-08 | 2.96e-01 | 0.067 |
| 101928287 | LINC01285 | LZE20T | Human | Esophagus | ESCC | 7.90e-04 | 3.61e-01 | 0.0662 |
| 101928287 | LINC01285 | LZE22T | Human | Esophagus | ESCC | 1.00e-09 | 6.30e-01 | 0.068 |
| 101928287 | LINC01285 | LZE24T | Human | Esophagus | ESCC | 7.41e-13 | 3.42e-01 | 0.0596 |
| 101928287 | LINC01285 | LZE6T | Human | Esophagus | ESCC | 5.26e-07 | 4.51e-01 | 0.0845 |
| 101928287 | LINC01285 | P2T-E | Human | Esophagus | ESCC | 1.78e-03 | 1.36e-01 | 0.1177 |
| 101928287 | LINC01285 | P5T-E | Human | Esophagus | ESCC | 7.28e-26 | 6.54e-01 | 0.1327 |
| 101928287 | LINC01285 | P8T-E | Human | Esophagus | ESCC | 3.50e-02 | 9.00e-02 | 0.0889 |
| 101928287 | LINC01285 | P23T-E | Human | Esophagus | ESCC | 4.97e-06 | 2.77e-01 | 0.108 |
| 101928287 | LINC01285 | P24T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.63e-01 | 0.1287 |
| 101928287 | LINC01285 | P26T-E | Human | Esophagus | ESCC | 4.24e-18 | 4.17e-01 | 0.1276 |
| 101928287 | LINC01285 | P28T-E | Human | Esophagus | ESCC | 9.35e-10 | 3.20e-01 | 0.1149 |
| 101928287 | LINC01285 | P31T-E | Human | Esophagus | ESCC | 8.56e-12 | 2.33e-01 | 0.1251 |
| 101928287 | LINC01285 | P40T-E | Human | Esophagus | ESCC | 2.18e-06 | 2.90e-01 | 0.109 |
| 101928287 | LINC01285 | P52T-E | Human | Esophagus | ESCC | 4.24e-18 | 5.51e-01 | 0.1555 |
| 101928287 | LINC01285 | P56T-E | Human | Esophagus | ESCC | 1.16e-08 | 8.30e-01 | 0.1613 |
| 101928287 | LINC01285 | P57T-E | Human | Esophagus | ESCC | 1.96e-05 | 1.90e-01 | 0.0926 |
| 101928287 | LINC01285 | P62T-E | Human | Esophagus | ESCC | 3.71e-20 | 4.09e-01 | 0.1302 |
| 101928287 | LINC01285 | P80T-E | Human | Esophagus | ESCC | 7.49e-49 | 1.62e+00 | 0.155 |
| 101928287 | LINC01285 | P83T-E | Human | Esophagus | ESCC | 2.90e-21 | 6.39e-01 | 0.1738 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |